Antithrombotic Treatment of Acute Coronary Syndrome
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Vascular Medicine".
Deadline for manuscript submissions: closed (30 September 2020) | Viewed by 82017
Special Issue Editor
2. Professor "antithrombotic therapy in cardiac catheter interventions" at University Medical Center Maastricht, Maastricht, The Netherlands
Interests: acute coronary syndrome; antithrombotic therapy; interventional cardiology; pharmacogenetics; thrombosis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
There is still much debate over which is the best antithrombotic treatment (ATT) for patients with acute coronary syndrome (ACS). Although the ESC guidelines recommend the use of aspirin and a stronger P2Y12 inhibitor (prasugrel or ticagrelor) in all patients, many of these patients are treated with the weaker agent clopidogrel. This is because clopidogrel costs less, but probably also because of the higher bleeding risk with the use of prasugrel and ticagrelor. Major bleeding predicts mortality with a similar strength as myocardial infarction. In addition, because elderly patients have been under-represented in the large randomized controlled trials, evidence for the use of the stronger P2Y12 inhibitors in the elderly is rather weak. Therefore, the individualization of dual antiplatelet therapy (DAPT) has been proposed. According to the ESC guidelines, individualization of DAPT could be done by using risk scores (PRECISE DAPT, and DAPT scores). These scores may also be useful for determining the duration of DAPT, which is another area of controversy in the field of ACS. The fast onset of action of antiplatelet agents is paramount in high-risk patients such as those presenting with ST-elevation myocardial infarction (STEMI). Even the stronger P2Y12 inhibitors prasugrel and ticagrelor fail to be active in the first hours of STEMI, and therefore, there is a need for the development of antiplatelet agents with very rapid onset.
This Special Issue will summarize, among other topics, the current optimal ATT of ACS, the new antithrombotic treatments (cangrelor, selatogrel), how to individualize DAPT, controversies in the optimal ATT, and how to handle ATT when bleeding occurs.
Assoc. Prof. Dr. Jurriën ten Berg
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute coronary syndrome
- antithrombotic therapy
- P2Y12 inhibition
- tailored therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.